The Pharmacokinetics (PK) of DOVATO (50 mg Dolutegravir (DTG)/ 300 mg Lamivudine (3TC)) Fixed-Dose Combination in HIV-Infected Patients

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Evaluation of Relationships Between AB-506 Related ALT Elevations and AB-506 Pharmacokinetics (PK), Metabolite Concentrations and Plasma Bile Acids

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Pharmacokinetics, Safety, and Tolerability of Dolutegravir + Rilpivirine (JULUCA) in Healthy Japanese Adults

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Dolutegravir (DTG) Plasma Concentrations Under Different Combinations Regimens for ART- Pre-Treated Adults Living With HIV

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Tacrolimus and Sirolimus Doses in an HIV-Infected, Kidney-Recipient, Patient Requiring a Cobicistat-Based Antiretroviral Regimen

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Systematic Review and Meta-Analysis of Adverse Perinatal Outcomes Associated With Prenatal Exposure to Protease Inhibitor Combination in Pregnant Women With HIV Infection

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

In Utero Exposure to Antiretroviral Drugs and Pregnancy Outcomes: A Secondary Analysis of the ANRS Pharmacovigilance Database From the ANRS-Sponsored HIV Research Studies

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Impact of the Hepatitis B Virus (HBV) Capsid Inhibitor, AB-506, on the Single Dose Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Targeting Nuclear Receptors to Prevent Cobicistat Hepatotoxicity

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

A Population Pharmacokinetic Analysis Assessing the Exposure of Raltegravir Once-Daily 1200mg in Pregnant Women Living With HIV

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Comparison of Relative Bioavailability of TIVICAY Neonatal Liquid Formulations to Pediatric Dispersible Tablets

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Impact of CYP2B6 Genotype, TB Therapy and Formulation on Efavirenz Pharmacokinetics in Infants and Children Under 40 Months of Age

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Mechanistic Modelling for the Quantitative Evaluation of ARV Penetration in Lymphatic Tissues

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

TFVdp/FTCtp Concentrations in Rectal Samples: No Correlation Between Epithelial Cells Collected by Cytobrush and Isolated CD4+ Cells

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Intracellular EFdA Pharmacology Differs Between Species: Implications for Preclinical Study Design

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Inflammation Affects Antiretrovirals Plasma and Intracellular Exposure

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Lack of a Pharmacokinetic (PK) Interaction Between HIV-1 Maturation Inhibitor (MI) GSK3640254 (GSK’254) and Oral Contraceptive (OC) Ethinyl Estradiol (EE)/Levonorgestrel (LNG)

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Lack of a Pharmacokinetic (PK) Interaction Between HIV-1 Maturation Inhibitor (MI) GSK3640254 and Dolutegravir

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Antiretroviral Drug-drug Interaction (DDI) Profile of Long-acting Cabotegravir and Rilpivirine

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Fostemsavir Drug-Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Patients With Multidrug Resistant HIV-1 Infection

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Open-Label, Drug-Drug Interaction Study between HIV-1 Maturation Inhibitor (MI) GSK3640254 and Tenofovir Alafenamide (TAF)/Emtricitabine (FTC) in Healthy Participants

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Pharmacokinetics, Safety, and Tolerability of Single- and Multiple Ascending Doses of Jnj-64417184, a Non-Nucleoside Inhibitor of Respiratory Syncytial Virus Polymerase, in Healthy Volunteers

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Single-Ascending Dose (SAD) Pharmacokinetics of Hepatitis B Virus (HBV)-Specific JNJ-73763989 in Non-Japanese and Japanese Healthy Volunteers (HV)

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Leveraging Reverse Transcriptase 2020 | Judith Currier

Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020